Clinical trial · Interventional
WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC
WHENII - Early Response Evaluation With 18F-2-fluoro-2-deoxy-D-glucose Fluorodeoxyglucose(FDG)- Positrons Emissions Tomography(PET)/CT and Liquid Biopsy in Patients With NSCLC (Non Small Cell Lung Cancer)
NCT03481101CI-TRIAL-00047582WHENIIunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Response evaluation with FDG-PET and free circulating DNA in patients with inoperable lung cancer of non small cell type during first treatment with chemotherapy or immunotherapy.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Circulating Tumor Cell | — | UNRESOLVED | — |
| Circulating Tumor DNA | — | UNRESOLVED | — |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/CT | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- All patients
- description
- Both patients receiving chemotherapy and immunotherapy are observed during the same intervention with PET/CT and liquid biopsy. No primary comparison are made between the groups.
- interventionNames
- Device: PET/CT
Primary outcomes (3)
- measure
- Observation of changes in metabolism in cancer cells during first treatment with chemotherapy or immunotherapy.
- timeFrame
- 3 months
- description
- Measure changes in standardized uptake value (SUV) in tumorcells by FDG-PET.
- measure
- Observation of changes in circulating tumor DNA during first treatment.
- timeFrame
- 3 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with non-small cell lung cancer (NSCLC) who is about to start treatment with chemo- or immune therapy. No prior treatment of the one given. * Measurable decease according to RECIST criteria * Age \> 18 years * Performance status 0-2 (0-1 for immunotherapy) * Understands and reads danish Exclusion Criteria: * Poor performance status * Secondary active cancer * Pregnancy * Dysregulated diabetes mellitus
References
Publications (0)
Data not yet available
No reference posted for this study.